Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The liver is essential for the synthesis of plasma proteins and integration of lipid metabolism. While the role of transcriptional networks in these processes is increasingly understood, less is known about post-transcriptional control of gene expression by RNA-binding proteins (RBPs). Here, we show that the RBP
vigilin
is upregulated in livers of obese mice and in patients with
fatty liver
disease. By using in vivo, biochemical and genomic approaches, we demonstrate that
vigilin
controls very-low-density lipoprotein (VLDL) secretion through the modulation of apolipoproteinB/Apob mRNA translation. Crosslinking studies reveal that
vigilin
binds to CU-rich regions in the mRNA coding sequence of Apob and other proatherogenic secreted proteins, including apolipoproteinC-III/Apoc3 and fibronectin/Fn1. Consequently, hepatic
vigilin
knockdown decreases VLDL/low-density lipoprotein (LDL) levels and formation of atherosclerotic plaques in Ldlr
-/-
mice. These studies uncover a role for
vigilin
as a key regulator of hepatic Apob translation and demonstrate the therapeutic potential of inhibiting
vigilin
for cardiovascular diseases.
...
PMID:The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation. 2766 11